Converge Bio

Other Information Technology · Wilmington, DE · Founded 2024 · Privately Held (backing)

Developer of a biotech platform designed to apply generative artificial intelligence to biological data for advancing drug discovery and development. Converge Bio is based in Wilmington, DE and was founded in 2024. It was valued at $90 million at its early-stage round in Jan 2026, the last priced event on record. It has raised $30.5 million across 1 recorded round; the latest was a $25 million Series A in Jan 2026.

PMV mark · valuation
$90.0M
Oct 2026
Priced at
its early-stage round
Jan 2026
Total raised
$30.5M
Last round
Early Stage VC (Series A)
Jan 2026

Who backs Converge Bio?

6 investors
InvestorType
Bessemer Venture PartnersGrowth equity
AWS StartupsOther
TLV PartnersVenture capital
Vintage (Private Equity)Venture capital
AuroraAxis Capital—
Intel Ignite—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Converge Bio investors

6 investors are on record for Converge Bio, including Bessemer Venture Partners, AWS Startups, TLV Partners and Vintage (Private Equity). The Series A in Jan 2026 drew 2 investors.

Free account
More of Converge Bio with a free account
  • ·Watch Converge Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 6 firms already write checks for companies like Converge Bio in other information technology. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View